Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes — Hypo-PrEA

Postprandial Hypoglycemia Clinical Trial

Official title:
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes: a Randomized, Placebo-controlled Study

Status Active, not recruiting

Clinical Trial Summary

This study is to analyze whether the SGLT2-inhibitor empagliflozin or the IL-1 receptor antagonist anakinra may improve postprandial hypoglycemia in subjects with prediabetes.

Clinical Trial Description

Subjects with prediabetes may develop postprandial hypoglycemia. This is probably due to a dysfunction of the insulin producing β-cell characterized by a delayed and exaggerated insulin secretion leading to an initial peak in glycaemia followed by a rapid fall and eventually resulting in hypoglycemia. The latter occurring typically within 1 to 3 hours after food intake. In patients with gastric bypass surgery and postprandial hypoglycemia the SGLT2-inhibitor empagliflozin and the IL-1 receptor antagonist anakinra reduced postprandial insulin release and prevented hypoglycemia. This study is to analyze whether a similar therapeutic approach using empagliflozin and anakinra may also improve postprandial hypoglycemia in subjects with prediabetes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05174507
Study type	Interventional
Source	University Hospital, Basel, Switzerland
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 24, 2022
Completion date	May 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03984370` - Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass	Phase 2
Completed	`NCT03200782` - Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study	N/A
Recruiting	`NCT05036317` - Empagliflozin for the Treatment of Postprandial Hypoglycemia	Phase 3
Completed	`NCT04330196` - Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.	N/A
Recruiting	`NCT04720859` - Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)	N/A
Completed	`NCT05676385` - Glucose Response to a Formula for Patients at Risk of Hypoglycaemia	N/A
Completed	`NCT04836273` - Treatment of Post-bariatric Hypoglycaemia	Phase 2
Recruiting	`NCT05513404` - The Scottish Fruit Study	N/A
Completed	`NCT01162499` - Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia	N/A
Recruiting	`NCT05401578` - Canakinumab for the Treatment of Postprandial Hypoglycemia	Phase 3